Oppenheimer Maintains A Balanced Outlook on ACADIA Pharmaceuticals Inc. (ACAD) For 2026

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the best innovative healthcare stocks on our list.

TheFly reported on February 6 that Oppenheimer raised its price target on ACAD to $23 from $21 and maintained a Perform rating on the shares. The firm maintains a balanced outlook on the company heading into 2026, following discussions with management and investors regarding recent updates and developments.

In addition, Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) reported earlier on February 2 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency had given its Marketing Authorization Application for trofinetide (DAYBUE) to treat Rett syndrome a negative trend vote in response to a recent oral explanation from the CHMP. ACAD intends to ask for a re-examination after the official opinion is adopted, even though the formal opinion is anticipated later in February.

Despite the disappointing result, CEO Catherine Owen Adams stressed that patients benefit from trofinetide's substantial clinical evidence that supports its approval in the United States, Canada, and Israel. Over 1,000 individuals are currently receiving active therapy worldwide, ranging in age from toddlers who have just received a diagnosis to adults with chronic illnesses. Results from clinical studies continue to align with current real-world research conducted in the United States. In order to provide trofinetide to patients with Rett syndrome in the EU, ACAD is still dedicated to collaborating with the EMA and other relevant parties.

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) is a U.S. biopharmaceutical innovator advancing therapies for underserved neurological and rare diseases, with the first‑ever FDA‑approved treatments for Parkinson’s disease psychosis and Rett syndrome, and a data‑driven pipeline leveraging precision science and AI to target unmet CNS needs.

While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.